Evaxion Biotech A/S Adr (EVAX) has released an update.
Evaxion Biotech A/S has launched a precision vaccine initiative using AI to identify new cancer targets and aims for preclinical proof-of-concept by H2 2024. The company completed key phases of a vaccine collaboration with MSD and secured significant funding through a private placement and a public offering, with MSD GHI becoming the largest shareholder. Evaxion’s R&D Day highlighted the potential of their AI-Immunology platform in vaccine discovery and the company’s strategy for value generation.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
